Third Pole Therapeutics – eNOfit – First Wearable Drug Making Platform

Bill Athenson, CEO of Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, discusses eNOfit™ the company’s proprietary, tankless, on-demand, electrically generated inhaled Nitric Oxide (iNO) technology that is a safe, accurate and reliable lightweight, wearable device that makes iNO from electricity and the air we breathe, creating a make it and take therapy free from the hazards of compressed gas storage. Their proprietary, versatile technology has the potential to rapidly capture the entire existing in-hospital tank-based market and expand beyond current indications to treat interstitial lung disease, chronic obstructive pulmonary disease, cystic fibrosis, and critical viral and bacterial infections. eNOfit devices are being tested in preparation for an FDA investigational device exemption (IDE) submission later this year to enable human safety testing to begin in early 2022. 

Bill leads Third Pole, bringing over 25 years of experience creating profitable organizations within the pharma, life sciences, medical device, molecular diagnostics and healthcare software markets on a global basis. He has a unique blend of Fortune 15 company experience balanced with early-stage medical technology roles, as well as demonstrated success in fund raising, strategy and leveraging high impact strategic partnerships. Most recently, Athenson served as CEO of Three Lakes Partners, conducting impact funding of pioneering drug discovery, diagnostics and medical device-based technologies and collaborations focused on accelerating therapies and improving care for patients living with Pulmonary Fibrosis. Bill has served on the Board of the Open Source Imaging Consortium, with the goal of leveraging AI to create an imaging biomarker that accurately detects fibrotic disease progression in the lungs. Bill was responsible for leading the successful global launch of a rapid molecular sepsis diagnostic platform at Nanosphere Inc. He has extensive experience in building and leading high performing cross functional device development, operations, and commercial groups from product concept through commercial execution across U.S., Europe, and Asia, with American Hospital Supply, Baxter Healthcare, Allegiance Healthcare and Cardinal Health. Bill received his MBA from the Kellogg School of Management at Northwestern University and a Bachelor of Science degree from Fordham University in New York.